0
Abstract: Poster Presentations |

EFFECT ON HAEMOPTYSIS IN REGARDS TO PYRAZINAMIDE CONTAINING V/S NON-PYRAZINAMIDE CONTAINING ANTI-TUBERCULAR REGIMEN IN PULMONARY TUBERCULOSIS CASES FREE TO VIEW

Charanpreet S. Grover, MBBS*; Vishal Chopra, MD; Amrit P. Kansal, MD; Ish Kumar, MD
Author and Funding Information

Govt. Medical College, Patiala, India


Chest


Chest. 2008;134(4_MeetingAbstracts):p130004. doi:10.1378/chest.134.4_MeetingAbstracts.p130004
Text Size: A A A
Published online

Abstract

PURPOSE: The aim of present study was to compare the effect of pyrazinamide on the duration and quatity of blood loss in patients of pulmonary tuberculosis with haemoptysis where one group was managed with Pyrazinamide(Z) containing anti-tuberculosis treatment (ATT) and the other group was managed with non-pyrazinamide containing ATT.

METHODS: The present study was conducted on 100 new cases of pulmonary tuberculosis (sputum positive for acid fast bacilli) with haemoptysis. During the study period of 15 days, the patients were divided into two groups of 50 patients each wherein group A was managed with pyrazinamide containing ATT i.e isoniazid (H), rifampicin (R), ethambutol (E) and pyrazinamide (Z) and group B were managed without pyrazinamide i.e HRE. History of any bleeding disorder in the patient or in the family was recorded. The quantity and duration of hemoptysis was compared in both the groups. Bleeding time (BT), coagulation time (CT), prothrombin time (PT), platelet count, serum calcium were estimated. Both the groups were administered respective treatments and estimation of all above mentioned parameters was done initially and after every five days for fifteen days.

RESULTS: There was no statistical difference in the quantity and duration of hemoptysis in both the groups. Pyrazinamide did not change BT, CT,PT, platelet count,serum calcium levels. Increased haemoptysis was seen in two percent patients in both the groups but it could not be specifically attributed to pyrazinamide.

CONCLUSION: Thus it is concluded that pyrazinamide in therapeutic doses neither increases the quatity or duration of hemoptysis nor does it upset the haemostatic mechanism and is also not responsible for the occurence of haemoptysis during treatment. Hence it is safe to give pyrazinamide during hemoptysis.

CLINICAL IMPLICATIONS: Pyrazinamide is a safe drug to be administered during hemoptysis.

DISCLOSURE: Charanpreet Grover, None.

Wednesday, October 29, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543